- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech High Insider Buying
Australian Pharmaceuticals & Biotech High Insider Buying
Results
16
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
16 companies
CSL
Market Cap: AU$115.9b
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$239.35
7D
-1.0%
1Y
-11.8%
Mesoblast
Market Cap: AU$2.1b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.65
7D
-4.9%
1Y
112.9%
Vita Life Sciences
Market Cap: AU$98.0m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$1.77
7D
-1.9%
1Y
-26.6%
Vitrafy Life Sciences
Market Cap: AU$89.1m
Provides cryopreservation solutions in Australia.
VFY
AU$1.40
7D
28.0%
1Y
n/a
Radiopharm Theranostics
Market Cap: AU$51.3m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.022
7D
4.8%
1Y
-51.1%
Alterity Therapeutics
Market Cap: AU$46.6m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.007
7D
-12.5%
1Y
40.0%
Vitura Health
Market Cap: AU$46.4m
Engages in the sale and distribution of medicinal cannabis products in Australia.
VIT
AU$0.07
7D
1.4%
1Y
-58.8%
Tryptamine Therapeutics
Market Cap: AU$46.0m
A clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States.
TYP
AU$0.032
7D
10.3%
1Y
n/a
Cynata Therapeutics
Market Cap: AU$44.1m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.20
7D
0%
1Y
-7.1%
IDT Australia
Market Cap: AU$43.0m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States.
IDT
AU$0.10
7D
-4.8%
1Y
5.3%
Cryosite
Market Cap: AU$38.1m
Provides outsourced clinical trials logistic services in Australia.
CTE
AU$0.78
7D
-1.9%
1Y
5.4%
Prescient Therapeutics
Market Cap: AU$36.2m
A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.
PTX
AU$0.045
7D
9.8%
1Y
-27.4%
Emyria
Market Cap: AU$14.7m
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
EMD
AU$0.03
7D
3.4%
1Y
-46.4%
Percheron Therapeutics
Market Cap: AU$13.0m
Engages in the research and development of novel antisense pharmaceuticals in Australia.
PER
AU$0.012
7D
20.0%
1Y
-84.2%
Acrux
Market Cap: AU$9.4m
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.023
7D
4.5%
1Y
-60.3%
Cambium Bio
Market Cap: AU$5.5m
A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.
CMB
AU$0.30
7D
7.1%
1Y
-66.7%